The Nitric Oxide Pathway-A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension

Am J Cardiol. 2017 Oct 15;120(8S):S69-S70. doi: 10.1016/j.amjcard.2017.06.011.

Authors

Thenappan Thenappan¹, E Kenneth Weir²

Affiliations

¹ Cardiovascular Division, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota. Electronic address: tthenapp@umn.edu.
² Cardiovascular Division, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota.

PMID: 29025572
DOI: 10.1016/j.amjcard.2017.06.011

No abstract available

Publication types

Introductory Journal Article
Research Support, Non-U.S. Gov't

MeSH terms

Cyclic GMP / metabolism
Drug Therapy, Combination
Endothelins / metabolism*
Enzyme Activators / therapeutic use
Humans
Hypertension, Pulmonary / drug therapy
Hypertension, Pulmonary / metabolism*
Molecular Targeted Therapy
Nitric Oxide / metabolism*
Phosphodiesterase 5 Inhibitors / therapeutic use
Precision Medicine*
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Signal Transduction
Sildenafil Citrate / therapeutic use
Tadalafil / therapeutic use

Substances

Endothelins
Enzyme Activators
Phosphodiesterase 5 Inhibitors
Pyrazoles
Pyrimidines
Nitric Oxide
Tadalafil
Sildenafil Citrate
Cyclic GMP
riociguat